Cargando…

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment

Detalles Bibliográficos
Autores principales:	Yopp, Adam, Kallinteris, Nikoletta, Huang, Xianming, Shan, Joe, Menander, Kerstin, Freimark, Bruce, Hutchins, Jeff, King, Steve, Gabrilovich, Dmitry I, Brekken, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292574/ http://dx.doi.org/10.1186/2051-1426-2-S3-P266

Ejemplares similares

Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma
por: Yopp, Adam, et al.
Publicado: (2014)

Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
por: Huang, Xianming, et al.
Publicado: (2015)

Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
por: Huang, Xianming, et al.
Publicado: (2014)

Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses
por: Gong, Jian, et al.
Publicado: (2013)

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
por: Gong, Jian, et al.
Publicado: (2014)

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
por: Belzile, Olivier, et al.
Publicado: (2018)

Phosphatidylserine-targeting antibody induces M1 macrophage polarization, promotes myeloid derived suppressor cell differentiation and boosts tumor-specific immunity
por: Huang, Xianming, et al.
Publicado: (2013)

New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay
por: Kallinteris, Nikoletta L, et al.
Publicado: (2015)

Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies
por: Sharma, Raghava, et al.
Publicado: (2017)

Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype
por: Hao, Xue, et al.
Publicado: (2020)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
por: Birge, R B, et al.
Publicado: (2016)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers
por: Gray, Michael J., et al.
Publicado: (2016)

First-in-Man Evaluation of (124)I-PGN650: A PET Tracer for Detecting Phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment
por: Laforest, Richard, et al.
Publicado: (2017)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: Harber, James, et al.
Publicado: (2021)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
por: Genova, Carlo, et al.
Publicado: (2022)

Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade
por: Fang, Tianxu, et al.
Publicado: (2023)

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
por: Gray, Michael, et al.
Publicado: (2015)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy
por: Wang, Weihong, et al.
Publicado: (2022)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023)

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
por: Sun, Lu, et al.
Publicado: (2023)

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
por: Luo, Hong, et al.
Publicado: (2023)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
por: Zhang, Yuqing, et al.
Publicado: (2021)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
por: Subramanian, Madhav, et al.
Publicado: (2023)

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
por: Pingili, Ajeeth K., et al.
Publicado: (2021)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade
por: Zheng, Weiwei, et al.
Publicado: (2022)

Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment
por: Falcomatà, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4hhm3j55mqng7fgdsur6t9opo4